KRAS and neoplasm: Other enriched pathways were associated with tumor progression, including the IL6/JAK/STAT3, KRAS, and PI3K/AKT/mTOR signaling pathways, which corresponded to the higher mutation rate of EGFR and PTEN in high-risk patients mentioned above.